Celiac disease is an immune-mediated enteropathy triggered by gluten ingestion. The effect of very small gluten exposures remains uncertain, contributing to international variations in food-labelling standards.
Interleukin-2 rises rapidly after gluten ingestion serving as a biomarker of immune activation. We aimed to identify the lowest gluten dose that elicits a measurable interleukin-2 response and accompanying symptoms in treated celiac disease.
Gastroenterology (AGA) published a clinical update in Research Highlights on 26 Mar 2026.
The item focuses on A Randomized Double-Blind, Placebo-Controlled Dose-Response Study to Assess the Gluten Threshold Dose in Celiac Disease.
Review the original article for the full source wording and details.